AU2013332272B2 - Improved human herpesvirus immunotherapy - Google Patents

Improved human herpesvirus immunotherapy Download PDF

Info

Publication number
AU2013332272B2
AU2013332272B2 AU2013332272A AU2013332272A AU2013332272B2 AU 2013332272 B2 AU2013332272 B2 AU 2013332272B2 AU 2013332272 A AU2013332272 A AU 2013332272A AU 2013332272 A AU2013332272 A AU 2013332272A AU 2013332272 B2 AU2013332272 B2 AU 2013332272B2
Authority
AU
Australia
Prior art keywords
protein
amino acid
ctl
cmv
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013332272A
Other languages
English (en)
Other versions
AU2013332272A1 (en
Inventor
Rajiv Khanna
Dasari VIJAYENDRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904604A external-priority patent/AU2012904604A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Priority to AU2013332272A priority Critical patent/AU2013332272B2/en
Publication of AU2013332272A1 publication Critical patent/AU2013332272A1/en
Priority to AU2018274961A priority patent/AU2018274961A1/en
Application granted granted Critical
Publication of AU2013332272B2 publication Critical patent/AU2013332272B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013332272A 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy Active AU2013332272B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013332272A AU2013332272B2 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy
AU2018274961A AU2018274961A1 (en) 2012-10-19 2018-12-06 Improved human herpesvirus immunotherapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012904604A AU2012904604A0 (en) 2012-10-19 Improved human cytomegalovirus immunotherapy protein
AU2012904604 2012-10-19
AU2013332272A AU2013332272B2 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy
PCT/AU2013/001216 WO2014059489A1 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018274961A Division AU2018274961A1 (en) 2012-10-19 2018-12-06 Improved human herpesvirus immunotherapy

Publications (2)

Publication Number Publication Date
AU2013332272A1 AU2013332272A1 (en) 2015-05-14
AU2013332272B2 true AU2013332272B2 (en) 2018-12-20

Family

ID=50487350

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013332272A Active AU2013332272B2 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy
AU2018274961A Abandoned AU2018274961A1 (en) 2012-10-19 2018-12-06 Improved human herpesvirus immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018274961A Abandoned AU2018274961A1 (en) 2012-10-19 2018-12-06 Improved human herpesvirus immunotherapy

Country Status (7)

Country Link
US (4) US9901632B2 (https=)
EP (3) EP2909238A4 (https=)
JP (4) JP2015533366A (https=)
CN (2) CN104918960B (https=)
AU (2) AU2013332272B2 (https=)
CA (1) CA2889064A1 (https=)
WO (1) WO2014059489A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909238A4 (en) 2012-10-19 2016-11-30 Queensland Inst Med Res IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS
NZ736675A (en) * 2015-05-12 2023-03-31 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
CN105030047A (zh) * 2015-08-31 2015-11-11 捷赛厨电（北京）科技有限公司 可控制油烟的炒锅
CN110234358A (zh) * 2016-07-18 2019-09-13 昆士兰医学研究所理事会 多病毒特异性的t细胞免疫疗法
BR112020012361A2 (pt) * 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
AU2019268545A1 (en) * 2018-05-18 2020-12-10 The Council Of The Queensland Institute Of Medical Research Adoptive T-cell therapy for CMV infection and CMV-associated diseases
US20210301255A1 (en) 2018-09-10 2021-09-30 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US11810904B2 (en) 2020-02-24 2023-11-07 PlayNitride Display Co., Ltd. Micro light emitting diode structure and manufacturing method thereof and micro light emitting diode device
CN111394376B (zh) * 2020-03-30 2023-04-28 济宁医学院 一种融合基因bfna、重组腺病毒及其制备方法和应用
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021356478A1 (en) * 2020-10-07 2023-06-01 The Council Of The Queensland Institute Of Medical Research Herpesvirus polyepitope vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007556A1 (en) * 2002-07-12 2004-01-22 Csl Limited Expression of hydrophobic proteins
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2012092934A1 (en) * 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
US6703024B2 (en) * 1996-05-24 2004-03-09 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7005131B1 (en) * 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
CA2500955A1 (en) 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
US20070048329A1 (en) 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
US20120052088A1 (en) * 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2909238A4 (en) 2012-10-19 2016-11-30 Queensland Inst Med Res IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007556A1 (en) * 2002-07-12 2004-01-22 Csl Limited Expression of hydrophobic proteins
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2012092934A1 (en) * 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides

Also Published As

Publication number Publication date
JP2021036882A (ja) 2021-03-11
JP7110302B2 (ja) 2022-08-01
US9901632B2 (en) 2018-02-27
EP2909238A4 (en) 2016-11-30
US11896665B2 (en) 2024-02-13
JP2018075034A (ja) 2018-05-17
CA2889064A1 (en) 2014-04-24
JP2019030331A (ja) 2019-02-28
US20210299248A1 (en) 2021-09-30
US20240156953A1 (en) 2024-05-16
CN104918960A (zh) 2015-09-16
CN118359733A (zh) 2024-07-19
US20180207261A1 (en) 2018-07-26
EP2909238A1 (en) 2015-08-26
US11065329B2 (en) 2021-07-20
CN104918960B (zh) 2024-06-14
US20150273051A1 (en) 2015-10-01
EP3872097A1 (en) 2021-09-01
JP6846396B2 (ja) 2021-03-24
AU2013332272A1 (en) 2015-05-14
JP2015533366A (ja) 2015-11-24
EP3466980A3 (en) 2019-05-01
EP3466980A2 (en) 2019-04-10
WO2014059489A1 (en) 2014-04-24
AU2018274961A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
US20240156953A1 (en) Human herpesvirus immunotherapy
DK1409527T3 (en) NOVEL cytotoxic T cell epitopes AND polyepitopes human cytomegalovirus (HCMV), compositions comprising them and diagnostic and prophylactic and therapeutic uses thereof
CA2552508A1 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2004525115A (ja) 抗原特異的免疫応答を誘起及び／又は増強する、２２〜４５アミノ酸残基からなる長いペプチド
Paillot et al. Characterisation of CTL and IFN-γ synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection
US20070048329A1 (en) Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
Liu et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein
HK40057947A (en) Improved human herpesvirus immunotherapy
HK40006634A (en) Improved human herpesvirus immunotherapy
US20230173061A1 (en) Human cytomegalovirus polyepitope vaccine composition
AU2024257980A1 (en) Timp3-derived teipp neoantigens and uses thereof
EP4698214A1 (en) Rcn1-derived teipp neoantigens and uses thereof
US20070237790A1 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)